Primary care diagnosis, assessment and management of COPD

Thematic Poster
Chairs: P. White (London, United Kingdom), T. Schermer (Nijmegen, Netherlands), M. Thomas (Southampton, United Kingdom), N. Chavannes (Leiden, Netherlands)

Evaluating a simple lung monitor as a screening test for COPD in primary care A. Dickens (BIRMINGHAM, United Kingdom)
Targeting the appropriate population for COPD screening in the primary care D. Spyratos (Thessaloniki, Greece)
Accuracy of COPD diagnosis in primary care in Knowsley, UK D. Wat (LIVERPOOL, United Kingdom)
Personalised prescribing for COPD patients: a primary care audit A. Morice (Cottingham, United Kingdom)
Quality of Life and Multicomponent scales in Chronic Obstructive Pulmonary Disease J. Gonzalvez Rey (Vigo (Pontevedra), Spain)
The distribution of COPD in UK general practice using the 2017 GOLD classification J. Haughney (Aberdeen, United Kingdom)
Refined ABCD assessment tool in COPD – results from the TIE-study J. Sulku (Gävle, Sweden)
Prediction of one or two years’ exacerbation free time in primary care COPD patients, a validated prediction nomogram N. Abu Hussein (Basel, Switzerland)
Prevalence of chronic obstructive pulmonary diseases related-hospitalization with acute exacerbation and its associated factors in Thailand. P. Kuwalairat (Chumphon, Thailand)
Evaluation of DECAF, CURB-65 and BAP-65 scales as predictor of mortality risk in acute exacerbation of COPD in a retrospective cohort A. Vílchez Parras (Torredelcampo (Jaén), Spain)
Gender and economic aspects of COPD in a Swedish cohort: The ARCTIC study K. Lisspers (Gagnef, Sweden)
Cardio-metabolic profile, function and physical activity in mild-moderate COPD patients A. Jones (Derby, United Kingdom)
Handgrip strength among COPD patients in the primary care D. Spyratos (Thessaloniki, Greece)
Occurrence and severity of morning symptoms in chronic obstructive pulmonary disease – a cross-sectional study A. van Buul (Leiden, Netherlands)
Estimating the number of patients’ needed to treat (NNT) with indacaterol/glycopyrronium to prevent COPD exacerbations: Results from the FLAME study L. Bjermer (Lund, Sweden)
Real-life evaluation of budesonide/formoterol (DuoResp Spiromax) for the management of asthma and COPD in the UK N. Roche (Paris, France)
Efficacy and safety of Long-acting Beta-agonists+Long-acting muscarinic antagonists vs Long-acting Beta-agonists+Inhaled corticosteroids in COPD: a meta-analysis R. Villalobos (Manila, Philippines)
Indacaterol/glycopyrronium (IND/GLY) is cost-effective compared with salmeterol/fluticasone (SFC) in Swedish chronic obstructive pulmonary disease (COPD) patients L. Bjermer (Lund, Sweden)
Patient demographics and clinical characteristics in the UK Salford Lung Study (SLS COPD) and the European ACCESS study M. Driessen (Brentford, United Kingdom)